Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias

NCT02041299 is registered in ClinicalTrials.gov with ApoPharma as lead sponsor.

NCT NCT02041299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02041299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias
Lead sponsor
ApoPharma
Phase
Phase 4
Overall status
Terminated
Start date
April 17, 2014
Completion date
June 18, 2019
Enrollment
230 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

iron overload, other anemias, sickle cell disease